Daeryung Technotown 17 Gasan digital 1-ro 25
Based in Seoul, South Korea, Eutilex is a clinical-stage biopharmaceutical company focused on the development of anti-tumor T cell and antibody therapeutics for the treatment of cancers and autoimmune diseases. The most advanced drug candidate is an adoptive T Cell therapy, which has finished Phase 1 clinical trials and will begin Phase 2. Other pipeline candidates in development include monoclonal antibodies, EU-101, EU-102 and EU-103.
Founder and CEO: Byoung S. Kwon
Please click here for Eutilex job opportunities.
Please click here for clinical trial information.